From: The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
GOLD I + II (n = 636) | GOLD III + IV (n = 710) | |
---|---|---|
Rate of decline in FEV1 | ||
Annual rate of decline, mL | 46 | 23 |
Difference, mL (95 % CI) | 23 (9, 38); p = 0.0017 | |
Rate of decline in FVC | ||
Annual rate of decline, mL | 55 | 37 |
Difference, mL (95 % CI) | 18 (−7, 43); p = 0.1658 | |
Rate of decline in FEV1/FVC | ||
Annual rate of decline, % | 0.51 | 0.26 |
Difference, % (95 % CI) | 0.25 (−0.12, 0.62); p = 0.1914 |